BioCentury
BioCentury
YouTubeLinkedInXRSS
ARTICLE | Distillery Therapeutics

Agonizing RARG to reduce doxorubicin-induced cardiotoxicity

By Claire Quang, Staff Writer
October 1, 2021 5:20 AM UTC

DISEASE CATEGORY: Cardiovascular

INDICATION: Organ damage...

BCIQ Company Profiles

Northwestern University Feinberg School of Medicine

Stanford University

BCIQ Target Profiles

Retinoic acid receptor gamma (RARG)

BCIQ Company Profiles

Northwestern University Feinberg School of Medicine

Stanford University

BCIQ Target Profiles

Retinoic acid receptor gamma (RARG)

About BioCentury

Privacy & Legal

Contact

About BioCentury

Company Overview
Management
Editorial & Research
Scientific Advisory Board

Privacy & Legal

User Agreement
Terms of Use
Privacy Policy
Use of Images & Market Data
Reprints & Permissions

Contact

Contact Us
Advertising & Sponsorship
Customer Resource Center
Career Opportunities
Forgot Password
YouTubeLinkedInXRSS
BioCentury
© 2025 BioCentury Inc. All Rights Reserved.
Copyright © 2025 BioCentury Inc. All Rights Reserved.
YouTubeLinkedInXRSS